Navigation Links
Kiadis Pharma Announces Continued Collaboration With Professor Velardi on its Lead Product ATIR(TM)
Date:11/28/2008

AMSTERDAM, Nov. 28 /PRNewswire/ -- Oncology focused biopharmaceutical company Kiadis Pharma announces today that Andrea Velardi, M.D., Professor of Clinical Immunology at the University of Perugia, Italy and Kiadis Pharma are continuing their collaboration on ATIR(TM), a product in clinical development for enabling the use of a mismatched donor in a bone marrow transplantation by preventing acute Graft versus Host Disease (GvHD) for end stage leukemia patients. Under the agreement Professor Velardi will continue the development on the selective depletion of allo-reactive T cells from mismatched donors using Kiadis Pharma's ATIR(TM). Kiadis Pharma is preparing for a multi-center pivotal study on ATIR(TM) to start early 2009 and Professor Velardi will participate in this upcoming study.

"We are very pleased with our continued collaboration with the University of Perugia and Professor Velardi, who is a leader in the field of mismatched bone marrow transplantations," says Dr. Manja Bouman, CEO of Kiadis Pharma. "This collaboration is an important milestone in the development of ATIR(TM) as a revolutionary approach to provide safe and potentially life-saving mismatched bone marrow transplantations as a treatment option for end-stage leukemia patients."

Professor Andrea Velardi says: "So far, we have treated 25 blood cancer patients who have received bone marrow from mismatched donors, including donor immune cells that are selectively depleted of cells causing acute Graft versus Host Disease using the ATIR(TM) process. The results so far are promising and I am therefore very pleased to continue to work with Kiadis Pharma in this field."

For the complete press release please go to: www.kiadis.com/news

About Kiadis Pharma

Kiadis Pharma is an oncology focused pharmaceutical development company with three products in different p
'/>"/>

SOURCE Kiadis Pharma
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related biology technology :

1. Kiadis Pharma Reports Successful End of Phase II Meeting With FDA for Reviroc
2. Kiadis Pharma Receives Orphan Drug Designation for Rhitol(TM) From the FDA
3. EMEA Grants Kiadis Pharma Lead Product ATIR(TM) Orphan Drug Designation
4. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
5. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
8. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
9. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2009)...ration of ultrasmall transistors and more powerful...onducting nanowires are closer to reality after a ...sity and the University of California at Los Angel... nanowires with layers of different materials that... a critical requirement for making efficient trans...
(Date:11/25/2009)...ytochromatodayannouncedtheappointmentofPeterMoldt,...ikSporkastheNovoA/SrepresentativeontheCompany,sBoa...bers. ,, "WeareverypleasedtowelcomePeterMoldtto...eandguidanceasCytochromacontinuestomakeprogressinb...ompany,"statedAlanLewis,PhD,ChairmanofCytochroma,s...
(Date:11/24/2009)...Call/--IES(Nasdaq: IESC ),aleadingnationalprovider...thecommercial,industrialandresidentialmarkets,anno...rdedacontractfromManhattanTorconJVtoinstalltheelec...cementfacilityattheU.S.ArmyMedicalResearchInstitut...erick,Md. ,, ThenewUSAMRIIDreplacementfacilityw...
(Date:11/24/2009)...Newswire-FirstCall/--deCODE,genetics,Inc.(Nasdaq: ...eNasdaqStockMarketthattradinginthecompany,scommons...NSEwillbefiledwiththe,SecuritiesandExchangeCommiss...onNasdaq,unlessthecompanyfilesanappealtotheNasdaq,...nappeal,which,willstaythesuspensionanddelistingthr...
Breaking Biology Technology:Nanowires key to future transistors, electronics 2Nanowires key to future transistors, electronics 3Cytochroma Announces Appointment of Peter Moldt to Board of Directors 2Integrated Electrical Services Awarded Contract to Provide Electrical Systems for U.S. Army Medical Research Institute of Infectious Diseases 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 3
...ombined Capabilities to Create One of the Industry...nology Offerings, BOSTON, June 13 PAREXEL Intern...obal biopharmaceutical services,organization, toda...al and,ClinPhone plc, a company traded on the Lond...ement on the terms of a recommended proposal where...
...EATTLE, June 13 On Thursday, June 19, 2008,at 7:0...:00 AM Pacific Time,members of Cell Therapeutics, ...m will host a Special Meeting in lieu of the Annua...ers located at 501 Elliott Ave.,West, Seattle, WA ...ebsite,at http://www.CellTherapeutics.com and ar...
... Against currently held dogma, scientists at the ...d that the interactions within membrane complexes ...pectrometer. Their research is published in this ...chers were surprised to discover that membrane com...en assumed that they would not survive once transf...
Other Biology Technology:PAREXEL Reaches Agreement To Acquire ClinPhone 2PAREXEL Reaches Agreement To Acquire ClinPhone 3PAREXEL Reaches Agreement To Acquire ClinPhone 4PAREXEL Reaches Agreement To Acquire ClinPhone 5Cell Therapeutics, Inc. Special Meeting in Lieu of Annual Meeting of Shareholders Scheduled for Thursday, June 19, 2008 2Membrane complexes take flight 2
(Date:11/26/2009)..., Mass. (November 26, 2009) Whitehead researchers...uman cells to pinpoint specific genes and proteins...cience . , In most human cell cultures genes are...her and one from the mother. Gene inactivation by ... copy is inactivated, the second copy usually rema...
(Date:11/25/2009)...a hormone produced in the stomach, may be used to ...arkinson,s disease, Yale School of Medicine resear...e of the Journal of Neuroscience . , Parkinson,...neurons in an area of the midbrain known as the su...production. Reduced production of dopamine in lat...
(Date:11/25/2009)...WI, NOVEMBER 25, 2009 Soil is the linchpin of the...rosphere meet. Despite that, many students see soi...ing more. Soil science educators are challenged wi...ognize the critical importance of soil in the envi...nce and earth science teachers at University of Ne...
Breaking Biology News(10 mins):Knockouts in human cells point to pathogenic targets 2Hormone ghrelin can boost resistance to Parkinson's disease 2It's not just dirt! 2Two Lehigh Valley Healthcare Leaders Collaborate to Deliver Safer High Quality Care to the Community 13720 1Two Lehigh Valley Healthcare Leaders Collaborate to Deliver Safer High Quality Care to the Community 13720 2Two Lehigh Valley Healthcare Leaders Collaborate to Deliver Safer High Quality Care to the Community 13720 3Two Lehigh Valley Healthcare Leaders Collaborate to Deliver Safer High Quality Care to the Community 13720 4President Bill Clinton to Speak at Inaugural Chicago House Speaker Series Luncheon 55524 1President Bill Clinton to Speak at Inaugural Chicago House Speaker Series Luncheon 55524 2NIH grant advances Tay Sachs disease gene therapy 55522 1NIH grant advances Tay Sachs disease gene therapy 55522 2NIH grant advances Tay Sachs disease gene therapy 55522 3
...on, tissue-specific molecular markers and precise ...ston and colleagues have possibly overturned a lon...c cells that give rise to connective and skeletal ... structures in back-boned creatures from fish to h...k Institute of Immunology in Germany and the Frenc...
...d with chainsaws and pry bars, University of Michi...ened the end for nearly 7,000 mature aspen and bir... glimpse the Great Lakes region,s future forests. ...ill it without cutting it down. , The main goal o...ed Succession Experiment (FASET) is to determine h...
...ternational team of scientists surveying the water...orth America has discovered for the first time hig...of the shoreline, raising concern for marine ecosy... the Wecoma, an Oregon State University research v...ied water that is being upwelled seasonally from t...
Other Biology News:Origin of cells for connective tissues of skull and face challenged 2Origin of cells for connective tissues of skull and face challenged 3U-M scientists remove thousands of aspens to glimpse forest's future 2U-M scientists remove thousands of aspens to glimpse forest's future 3Pacific coast turning more acidic 2Pacific coast turning more acidic 3
RDF (R106-05) from European Collection of Cell Cultures (ECACC)
...The Brownlee Precision Model 440 incorporates four...rcuitry in a friendly easy-to-use instrument. Each...er, an 8-pole Bessel lowpass filter, a highpass fi...ols. A control knob sets the amplifier parameters ...
REK (R102-05) from European Collection of Cell Cultures (ECACC)
PCAEC (P300-05) from European Collection of Cell Cultures (ECACC)
Biology Products: